• 13F History

Kohlberg Kravis Roberts & Co. L.P.

13F Filings History

Latest 13F report
Q4 2024 - Feb 14, 2025
Value $
$3.73B
Signature - Title
Lew Breckenridge - Managing Director
Location
New York, NY
Summary
This page shows a list of all the recent 13F filings made by Kohlberg Kravis Roberts & Co. L.P.. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Kohlberg Kravis Roberts & Co. L.P. reported 68 stock holdings with total value $3.73B as of Q4 2024. Top holdings included BTSG, BBIO, BV, KREF, and DASH.
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q4 2024 68 $3.73B +$60.1M -$4.08B -$4.02B BTSG, BBIO, BV, KREF, DASH 13F-HR 2/14/2025, 12:35 PM
Q3 2024 72 $7.47B +$3.95B -$340M +$3.61B OS, BTSG, BBIO, BV, PGRU 13F-HR 11/14/2024, 03:01 PM
Q2 2024 69 $3.33B +$165M -$650M -$484M BTSG, BBIO, BV, PGRU, KREF 13F-HR 8/14/2024, 04:55 PM
Q1 2024 67 $3.88B +$1.04B -$650M +$393M BBIO, BTSG, BV, PGRU, TGAN 13F-HR 5/15/2024, 03:54 PM
Q4 2023 71 $3.38B +$128M -$170M -$41M BBIO, BV, FSK, APP, PGRU 13F-HR 2/14/2024, 02:39 PM
Q3 2023 73 $2.85B +$148M -$1.15B -$1B BBIO, BV, FSK, APP, PGRU Restatement 1/22/2024, 10:27 AM
Q2 2023 89 $3.23B +$135M -$932M -$797M APP, BBIO, FSK, BV, PGRU 13F-HR 8/14/2023, 11:35 AM
Q1 2023 82 $3.32B +$88.4M -$116M -$27.9M APP, BBIO, FSK, BV, PGRU 13F-HR 5/15/2023, 03:42 PM
Q4 2022 126 $2.96B +$155M -$8.86M +$147M APP, BV, FSK, BBIO, EDR 13F-HR 2/14/2023, 11:08 AM
Q3 2022 205 $4.98B +$66.2M -$1.46B -$1.39B APP, FI, BV, LAUR, FSK 13F-HR 11/14/2022, 09:08 AM
Q2 2022 243 $7.52B +$169M -$1B -$834M FI, APP, BV, FSK, LAUR 13F-HR 8/12/2022, 04:12 PM
Q1 2022 266 $11B +$881M -$3.01B -$2.13B APP, FI, BV, FSK, EDR 13F-HR 5/16/2022, 04:48 PM
Q4 2021 206 $18.2B +$548M -$3.05B -$2.5B APP, FI, EDR, BV, KNBE 13F-HR 2/14/2022, 01:09 PM
Q3 2021 185 $20.1B +$456M -$4.18B -$3.73B APP, FI, BBIO, BV, KNBE 13F-HR 11/15/2021, 05:07 PM
Q2 2021 141 $24.7B +$10.5B -$5.33B +$5.15B APP, FI, BBIO, IR, ASO 13F-HR 8/16/2021, 02:14 PM
Q1 2021 101 $19.8B +$376M -$1.41B -$1.03B FI, IR, BBIO, ASO, BV 13F-HR 5/17/2021, 04:41 PM
Q4 2020 60 $19.7B +$1.51B -$2.41B -$899M FI, BBIO, IR, ASO, BV 13F-HR 2/16/2021, 04:01 PM
Q3 2020 64 $17.3B +$608M -$575M +$32.4M FI, IR, BBIO, BV, KREF 13F-HR 11/16/2020, 04:00 PM
Q2 2020 67 $16.4B +$758M -$930M -$172M FI, IR, BBIO, BV, KREF 13F-HR 8/14/2020, 05:02 PM
Q1 2020 50 $15.7B +$1.97B -$164M +$1.8B FI, IR, BBIO, BV, KREF 13F-HR 5/15/2020, 05:19 PM
Q4 2019 54 $20.5B +$363M -$60.5M +$302M FI, GDI, BBIO, BV, KREF 13F-HR 2/14/2020, 03:01 PM
Q3 2019 51 $17.8B +$11.7B -$149M +$11.6B FI, GDI, BV, BBIO, KREF 13F-HR 11/14/2019, 03:02 PM
Q2 2019 54 $8.1B +$1.22B -$65.3M +$1.16B GDI, BV, BBIO, PRAH, KREF 13F-HR 8/14/2019, 04:00 PM
Q1 2019 55 $6.57B +$746M -$117M +$629M GDI, BV, PRAH, KREF, FOCS 13F-HR 5/15/2019, 04:01 PM
Q4 2018 56 $5.48B +$537M -$1.11B -$568M GDI, PRAH, BV, KREF, EYE 13F-HR 2/13/2019, 03:06 PM
Q3 2018 59 $8.82B +$1.41B -$1.54B -$126M GDI, BV, EYE, PRAH, KREF 13F-HR 11/14/2018, 03:03 PM
Q2 2018 50 $8.78B +$1.84B -$1.39B +$449M GDI, BV, PRAH, EYE, KREF 13F-HR 8/14/2018, 04:02 PM
Q1 2018 42 $8.22B +$228M -$657M -$429M GDI, PRAH, EYE, KREF, GDDY 13F-HR 5/15/2018, 04:05 PM
Q4 2017 52 $10.2B +$2.36B -$878M +$1.48B GDI, EYE, PRAH, KREF, GDDY 13F-HR 2/14/2018, 03:30 PM
Q3 2017 1 $73.5M WRD New Holdings 2/14/2018, 03:37 PM
Q3 2017 53 $8.66B +$365M -$1.4B -$1.04B GDI, PRAH, USFD, KREF, GDDY 13F-HR 11/14/2017, 03:23 PM
Q2 2017 1 $68.3M WRD New Holdings 2/14/2018, 03:25 PM
Q2 2017 2 $511M KREF, VRS New Holdings 11/14/2017, 03:15 PM
Q2 2017 48 $8.83B +$4.1B -$860M +$3.24B GDI, PRAH, USFD, KREF, GDDY 13F-HR 8/14/2017, 04:05 PM
Q1 2017 1 $60K VRS New Holdings 11/14/2017, 03:08 PM
Q1 2017 1 $9.79M NOMD New Holdings 6/29/2017, 05:00 PM
Q1 2017 51 $5.57B +$293M -$903M -$610M USFD, PRAH, GDDY, EGL, AMED 13F-HR 5/15/2017, 04:32 PM
Q4 2016 1 $71K VRS New Holdings 11/14/2017, 03:05 PM
Q4 2016 54 $6.27B +$615M -$493M +$122M USFD, PRAH, GDDY, HCA, EGL 13F-HR 2/14/2017, 03:33 PM
Q3 2016 1 $65K VRS New Holdings 11/14/2017, 03:02 PM
Q3 2016 57 $8.06B +$501M -$1.29B -$784M USFD, WBA, PRAH, GDDY, HCA 13F-HR 11/14/2016, 03:46 PM
Q2 2016 50 $9.44B +$2.59B -$2.76B -$170M WBA, USFD, PRAH, GDDY, ZBH 13F-HR 8/15/2016, 05:11 PM
Q1 2016 53 $10.1B +$331M -$334M -$3.15M WBA, PRAH, HCA, ZBH, GDDY 13F-HR 5/16/2016, 05:23 PM
Q4 2015 55 $10.3B +$883M -$58.4M +$824M WBA, PRAH, HCA, ZBH, GDDY Restatement 4/1/2016, 05:18 PM
Q3 2015 69 $9.41B +$461M -$44.7M +$417M WBA, PRAH, HCA, ZBH, GDDY Restatement 4/1/2016, 05:07 PM
Q2 2015 58 $11.1B +$1.73B -$308M +$1.42B WBA, PRAH, HCA, SJM, ZBH Restatement 4/1/2016, 05:05 PM
Q1 2015 90 $9.65B +$1.84B -$206M +$1.63B WBA, PRAH, HCA, SJM, NLSN 13F-HR 5/15/2015, 04:49 PM
Q4 2014 82 $7.66B +$5.11B -$273M +$4.83B WBA, HCA, PRAH, NLSN, RNET 13F-HR 2/17/2015, 04:04 PM
Q3 2014 88 $3.53B +$633M -$82M +$551M HCA, NLSN, WAG, RNET, KKR 13F-HR 11/14/2014, 04:22 PM
Q2 2014 78 $3.4B +$466M -$1.49B -$1.02B HCA, NLSN, WAG, RNET, KKR 13F-HR 8/14/2014, 04:38 PM
Q1 2014 134 $5.96B +$1.23B -$697M +$534M HCA, NLSN, MRVLXXXX, NXPI, WAG Restatement 8/14/2014, 04:33 PM
Q4 2013 126 $5.95B HCA, NLSN, NXPI, MRVLXXXX, JAZZ 13F-HR 2/14/2014, 03:20 PM